Clincosm LogoSign in Get a demo

Management of Prostate Cancer in Central China

Sponsor
Zhengzhou University (Other)
Overall Status
Completed
CT.gov ID
NCT01614548
Collaborator
The First Affiliated Hospital of Zhengzhou University (Other), the cancer hospital of Zhengzhou University (Other), Third Affiliated Hospital of Zhengzhou University (Other), People's Hospital of Zhengzhou University (Other), Xinyang Central Hospital (Other), Zhoukou Central Hospital (Other), Center hospital of Nanyang (Other), Center hospital of Shangqiu (Other), Center hospital of Zhumadian (Other), Anyang Regional Hospital (Other), Luoyang Central Hospital (Other), First People's Hospital of Kaifeng (Other)
789
Enrollment
1
Location
107
Duration (Months)
7.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Some recent reports indicate that incidence of prostate cancer is increasing rapidly in China. However, no large-scale survey of prostate cancer has been done in central China, few data are available regarding its management. The investigators aimed to analyze the management of prostate cancer and compare the outcome of patients with such a survey.

The investigators collected data of patients diagnosed with prostate cancer from the 2003 and 2008 in central China. Data were disaggregated by rural and urban hukou. The survival rate of patients was analyzed using Kaplan-Meier method. Prognostic factors were analyzed using the log-rank test and Cox proportional hazards model.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    789 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Comparisons of Management and Outcome of Prostate Cancer in Central China Between 2003 and 2008: A Multi-institutional Report
    Study Start Date :
    Jan 1, 2003
    Actual Primary Completion Date :
    Dec 1, 2011
    Actual Study Completion Date :
    Dec 1, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    all patients

    We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.

    Outcome Measures

    Primary Outcome Measures

    1. overall survival [3 years]

      overall survival that was defined as the interval from the date of diagnosis to the Medicare date of death

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients with newly diagnosed prostate cancer were included in the study. Exclusion
    Criteria:
    • Those with a history of prostate cancer who were treated for another disease were excluded from study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 the first affiliated hospital of Zhengzhou University Zhengzhou Henan China 450052

    Sponsors and Collaborators

    • Zhengzhou University
    • The First Affiliated Hospital of Zhengzhou University
    • the cancer hospital of Zhengzhou University
    • Third Affiliated Hospital of Zhengzhou University
    • People's Hospital of Zhengzhou University
    • Xinyang Central Hospital
    • Zhoukou Central Hospital
    • Center hospital of Nanyang
    • Center hospital of Shangqiu
    • Center hospital of Zhumadian
    • Anyang Regional Hospital
    • Luoyang Central Hospital
    • First People's Hospital of Kaifeng

    Investigators

    • Principal Investigator: Liu Bingqian, Ph.D MD, The First Affiliated Hospital of Zhengzhou University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Liu Bingqian, Principal Investigator, Zhengzhou University
    ClinicalTrials.gov Identifier:
    NCT01614548
    Other Study ID Numbers:
    • ZZU2012
    First Posted:
    Jun 8, 2012
    Last Update Posted:
    Jun 8, 2012
    Last Verified:
    Jun 1, 2012
    Keywords provided by Liu Bingqian, Principal Investigator, Zhengzhou University
    Prostatic Neoplasms
    Prostate Cancer
    Disease Management
    Rural
    Urban
    Additional relevant MeSH terms:
    Prostatic Neoplasms

    Study Results

    No Results Posted as of Jun 8, 2012